Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes

Helen K Reddel, Leonard B Bacharier, Eric D Bateman, Christopher E Brightling, Guy G Brusselle, Roland Buhl, Alvaro A Cruz, Liesbeth Duijts, Jeffrey M Drazen, J Mark FitzGerald, Louise J Fleming, Hiromasa Inoue, Fanny W Ko, Jerry A Krishnan, Mark L Levy, Jiangtao Lin, Kevin Mortimer, Paulo M Pitrez, Aziz Sheikh, Arzu A Yorgancioglu, Louis-Philippe Boulet, Helen K Reddel, Leonard B Bacharier, Eric D Bateman, Christopher E Brightling, Guy G Brusselle, Roland Buhl, Alvaro A Cruz, Liesbeth Duijts, Jeffrey M Drazen, J Mark FitzGerald, Louise J Fleming, Hiromasa Inoue, Fanny W Ko, Jerry A Krishnan, Mark L Levy, Jiangtao Lin, Kevin Mortimer, Paulo M Pitrez, Aziz Sheikh, Arzu A Yorgancioglu, Louis-Philippe Boulet

Abstract

The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting β2-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by ⩾60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, "MART") in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting β2-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.

Keywords: asthma; asthma diagnosis; asthma management; asthma prevention.

Figures

Figure 1.
Figure 1.
Global Initiative for Asthma assessment of asthma control in adults, adolescents, and children 6–11 years. For a version of this figure with full reference citations, please see Box 2-2 in Reference . P450 inhibitors include cytochrome P450 inhibitors such as ritonavir, ketoconazole, and itraconazole. *Based on SABA (as-needed ICS–formoterol reliever not included); excludes reliever taken before exercise. For children 6–11 years, see also Box 2-3 in Reference . For specific risk reduction strategies, see Box 3-8 in Reference . †“Independent” risk factors are those that are significant after adjustment for the level of symptom control. Reproduced by permission from Reference (Box 2-2). BD = bronchodilator; FeNO = fractional exhaled nitric oxide; GERD = gastroesophageal reflux disease; ICS = inhaled corticosteroid; OCS = oral corticosteroid; SABA = short-acting β2-agonist.
Figure 2.
Figure 2.
Personalized asthma management cycle of care. Reproduced by permission from Reference (Box 3-2).
Figure 3.
Figure 3.
Personalized management for adults and adolescents to control symptoms and minimize risk. For ICS doses, see Box 3-6 in Reference . Reproduced by permission from Reference (Box 3-5A). HDM = house dust mite; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist; LTRA = leukotriene receptor antagonist; OCS = oral corticosteroid; SABA = short-acting β2-agonist; SLIT = sublingual immunotherapy.
Figure 4.
Figure 4.
Personalized management for children 6–11 years to control symptoms and minimize future risk. For ICS doses for children, see Box 3-6 in Reference . For MART doses, see Table E2 and the downloadable resource in the online supplement. Reproduced by permission from Reference (Box 3-5B). BUD-FORM = budesonide–formoterol; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; LTRA = leukotriene receptor antagonist; MART = maintenance-and-reliever therapy; OCS = oral corticosteroid; SABA = short-acting β2-agonist.
Figure 5.
Figure 5.
Management of asthma exacerbations in primary care (adults, adolescents, children 6–11 yr). SABA doses are for albuterol. Reproduced by permission from Reference (Box 4-3). PEF = peak expiratory flow; pMDI = pressurized metered-dose inhaler; SABA = short-acting β2-agonist.
Figure 6.
Figure 6.
Personalized management of asthma in children 5 years and younger. Reproduced by permission from Reference (Box 6-5). ICS = inhaled corticosteroid; LTRA = leukotriene receptor antagonist; SABA = short-acting β2-agonist.

References

    1. Global Asthma Network. The global asthma report 2018 Auckland, New Zealand: Global Asthma Network; 2018. [accessed 2021 Sep]. Available from:
    1. National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program; World Health Organization; National Institutes of Health Publication No. 95-3659. Global Initiative for Asthma. Bethesda, MD: National Institutes of Health; 1995.
    1. Global Initiative for Asthma Methodology. Fontana, WI: Global Initiative for Asthma; 2021. [accessed 2021 Sep]. Available from:
    1. Global Initiative for Asthma. Global strategy for asthma management and prevention Fontana, WI: Global Initiative for Asthma; 2021. [accessed 2021 Sep]. Available from:
    1. Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemière C, et al. Canadian Respiratory Research Network Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA . 2017;317:269–279.
    1. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med . 2009;180:59–99.
    1. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol . 2009;124:719–23, e1.
    1. Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med . 2005;99:553–558.
    1. Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations Allergy 200762591–604.. [Published erratum appears in Allergy 62:968].
    1. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J . 2005;26:948–968.
    1. Barnes PJ, Szefler SJ, Reddel HK, Chipps BE. Symptoms and perception of airway obstruction in asthmatic patients: clinical implications for use of reliever medications. J Allergy Clin Immunol . 2019;144:1180–1186.
    1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Eur Respir J 201443343–373.. [Published erratum appears in Eur Respir J 43:1216].
    1. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. A GINA pocket guide for health professionals. Version 3 Fontana, WI: Global Initiative for Asthma; 2021. [created 2021 Apr; accessed 2021 Sep]. Available from:
    1. Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet . 2017;389:157–166.
    1. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Novel START Study Team Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med . 2019;380:2020–2030.
    1. Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. PRACTICAL Study Team Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet . 2019;394:919–928.
    1. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J . 2016;47:410–419.
    1. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. START Investigators Group Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet . 2003;361:1071–1076.
    1. Pinnock H, Parke HL, Panagioti M, Daines L, Pearce G, Epiphaniou E, et al. PRISMS and RECURSIVE Groups Systematic meta-review of supported self-management for asthma: a healthcare perspective. BMC Med . 2017;15:64.
    1. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax . 2002;57:880–884.
    1. O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide–formoterol as needed in mild asthma. N Engl J Med . 2018;378:1865–1876.
    1. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med . 2000;343:332–336.
    1. O’Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW, START Investigators Group Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med . 2009;179:19–24.
    1. Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA . 2018;319:1485–1496.
    1. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev . 2013:CD007313.
    1. Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, et al. American Thoracic Society Subcommittee on Exercise-induced Bronchoconstriction An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med . 2013;187:1016–1027.
    1. Lazarinis N, Jørgensen L, Ekström T, Bjermer L, Dahlén B, Pullerits T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax . 2014;69:130–136.
    1. Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J . 2019;53:1901046.
    1. Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open . 2017;7:e016688.
    1. Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med . 2000;94:767–771.
    1. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet . 1993;342:833–837.
    1. Pavord ID, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Novel START Study Team Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med . 2020;8:671–680.
    1. Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med . 2018;378:1877–1887.
    1. O’Byrne P, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, et al. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med . 2021;9:149–158.
    1. Buhl R, Kuna P, Peters MJ, Andersson TL, Naya IP, Peterson S, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res . 2012;13:59.
    1. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med . 2007;101:2437–2446.
    1. Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol . 2012;109:403–407.
    1. Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J . 2020;55:1901872.
    1. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ . 2017;357:j1415.
    1. Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy . 2018;11:193–204.
    1. Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care . 2015;60:455–468.
    1. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al. BEST Study Group Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med . 2007;356:2040–2052.
    1. Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA . 2012;308:987–997.
    1. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF, Jr, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet . 2011;377:650–657.
    1. Sumino K, Bacharier LB, Taylor J, Chadwick-Mansker K, Curtis V, Nash A, et al. A pragmatic trial of symptom-based inhaled corticosteroid use in African-American children with mild asthma. J Allergy Clin Immunol Pract . 2020;8:176–185, e2.
    1. Demoly P, Louis R, Søes-Petersen U, Naya I, Carlsheimer A, Worth H, et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med . 2009;103:1623–1632.
    1. Vogelmeier C, D’Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J . 2005;26:819–828.
    1. Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, et al. SMART Study Group Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med . 2013;1:32–42.
    1. Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med . 2013;1:23–31.
    1. Bateman ED, Harrison TW, Quirce S, Reddel HK, Buhl R, Humbert M, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res . 2011;12:38.
    1. Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J . 2018;51:1701688.
    1. Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest . 2006;130:1733–1743.
    1. Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, et al. VESTRI Investigators Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med . 2016;375:840–849.
    1. Murphy VE, Gibson PG. Asthma in pregnancy. Clin Chest Med . 2011;32:93–110.
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of COPD Fontana, WI: Global Initiative for Chronic Obstructive Lung Disease; 2021. [accessed 2021 Sep]. Available from:
    1. Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA . 2014;312:1114–1121.
    1. Suissa S, Ernst P. Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned. Chest . 2018;154:257–265.
    1. Kendzerska T, Aaron SD, To T, Licskai C, Stanbrook M, Vozoris NT, et al. Effectiveness and safety of inhaled corticosteroids in older individuals with chronic obstructive pulmonary disease and/or asthma: a population study. Ann Am Thorac Soc . 2019;16:1252–1262.
    1. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol . 2015;135:896–902.
    1. Foster JM, McDonald VM, Guo M, Reddel HK. “I have lost in every facet of my life”: the hidden burden of severe asthma. Eur Respir J . 2017;50:1700765.
    1. Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, et al. IRIDIUM Trial Investigators Once-Daily, Single-Inhaler Mometasone-Indacaterol-Glycopyrronium versus Mometasone-Indacaterol or Twice-Daily Fluticasone-Salmeterol in Patients with Inadequately Controlled Asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med . 2020;8:1000–1012.
    1. Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet . 2019;394:1737–1749.
    1. Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med . 2021;9:69–84.
    1. Casale TB, Aalbers R, Bleecker ER, Meltzer EO, Zaremba-Pechmann L, de la Hoz A, et al. Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics. Respir Med . 2019;158:97–109.
    1. Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA . 2018;319:1473–1484.
    1. Hiles SA, McDonald VM, Guilhermino M, Brusselle GG, Gibson PG. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J . 2019;54:1901381.
    1. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev . 2017:CD005603.
    1. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J . 2020;55:1900588.
    1. Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol . 2015;136:1488–1495.
    1. Blaiss MS, Nathan RA, Stoloff SW, Meltzer EO, Murphy KR, Doherty DE. Patient and physician asthma deterioration terminology: results from the 2009 Asthma Insight and Management Survey. Allergy Asthma Proc . 2012;33:47–53.
    1. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax . 2004;59:94–99.
    1. McKeever T, Mortimer K, Wilson A, Walker S, Brightling C, Skeggs A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med . 2018;378:902–910.
    1. Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med . 2009;360:339–353.
    1. van den Berge M, Arshad SH, Ind PW, Magnussen H, Hamelmann E, Kanniess F, et al. Similar efficacy of ciclesonide versus prednisolone to treat asthma worsening after steroid tapering. Respir Med . 2009;103:1216–1223.
    1. Wilson AM, Lipworth BJ. Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Br J Clin Pharmacol . 1999;48:579–585.
    1. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J, Canadian Asthma Exacerbation Study Group Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax . 2004;59:550–556.
    1. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet . 2004;363:271–275.
    1. Perrin K, Wijesinghe M, Healy B, Wadsworth K, Bowditch R, Bibby S, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax . 2011;66:937–941.
    1. Patel B, Khine H, Shah A, Sung D, Medar S, Singer L. Randomized clinical trial of high concentration versus titrated oxygen use in pediatric asthma. Pediatr Pulmonol . 2019;54:970–976.
    1. Siemieniuk RAC, Chu DK, Kim LH, Güell-Rous MR, Alhazzani W, Soccal PM, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ . 2018;363:k4169.
    1. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev . 2013:CD000052.
    1. Selroos O. Dry-powder inhalers in acute asthma. Ther Deliv . 2014;5:69–81.
    1. Travers AH, Milan SJ, Jones AP, Camargo CA, Jr, Rowe BH. Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database Syst Rev . 2012:CD010179.
    1. Rodrigo GJ, Neffen H, Colodenco FD, Castro-Rodriguez JA. Formoterol for acute asthma in the emergency department: a systematic review with meta-analysis. Ann Allergy Asthma Immunol . 2010;104:247–252.
    1. Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther . 2006;19:139–147.
    1. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev . 2003:CD001117.
    1. Schatz M, Rachelefsky G, Krishnan JA. Follow-up after acute asthma episodes: what improves future outcomes? Proc Am Thorac Soc . 2009;6:386–393.
    1. U.S. Food and Drug Administration. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis Silver Spring, MD: U.S. Food and Drug Administration; 2020. [accessed 2021 Sep]. Available from:
    1. Kaiser SV, Huynh T, Bacharier LB, Rosenthal JL, Bakel LA, Parkin PC, et al. Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. Pediatrics . 2016;137:e20154496.
    1. Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Global Allergy and Asthma European Network Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol . 2010;126:466–476.
    1. Beasley R, Semprini A, Mitchell EA. Risk factors for asthma: is prevention possible? Lancet . 2015;386:1075–1085.
    1. Boulet LP, FitzGerald JM, Levy ML, Cruz AA, Pedersen S, Haahtela T, et al. A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. Eur Respir J . 2012;39:1220–1229.
    1. Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet . 2021;397:928–940.
    1. Asher I, Bissell K, Chiang CY, El Sony A, Ellwood P, García-Marcos L, et al. Calling time on asthma deaths in tropical regions-how much longer must people wait for essential medicines? Lancet Respir Med . 2019;7:13–15.
    1. World Health Organization. WHO model lists of essential medicines Geneva, Switzerland: World Health Organization; 2021. [accessed 2021 Sep]. Available from:
    1. Sanyang B, Jagne E, Sefa N, Touray S. Availability, cost, and affordability of asthma and chronic obstructive pulmonary disease medications in The Gambia. J Pan Afr Thorac Soc . 2021;2:33–41.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する